Dr CHEUNG Ka Shing, Michael

Dr Michael Cheung

Clinical Assistant Professor

  • MBBS(HK) MD(HK) MPH(HK) MRCP(UK) FRCP(Edin) FHKCP FHKAM (Medicine)
Biography

Dr. Michael Ka Shing Cheung graduated from The University of Hong Kong in 2008, and received his Fellowship in Gastroenterology and Hepatology from the Hong Kong College of Physicians in 2015 and Fellowship from the Royal College of Physicians of Edinburgh in 2021. He obtained his Master of Public Health degree with distinction in 2016 and Doctor of Medicine degree (with Sir Patrick Manson Gold Medal) in 2020. He is currently the Clinical Assistant Professor in the Department of Medicine, the University of Hong Kong, Hong Kong. He is also the associate consultant in the University of Hong Kong-Shenzhen Hospital, Shenzhen, China, and honorary associate consultant in Queen Mary Hospital. Dr. Cheung’s research interests are gastrointestinal and hepatobiliary oncology (including gastric cancer, colorectal cancer, liver cancer), gut microbiota, gastrointestinal bleeding, inflammatory bowel disease, liver diseases (including hepatitis B virus, fatty liver, cirrhosis, liver cancer) and COVID-19 disease. He is experienced in various kinds of study design including randomized controlled trial, prospective cohort study, and retrospective cohort study (with particular focus on Big Data analysis). He has published 84 international peer-reviewed journal articles since 2016, including first- and corresponding-authored articles in Gut (impact factor 23.059), Gastroenterology (impact factor 22.682), Diabetes Care (impact factor 19.112), Journal of the National Cancer Institute (impact factor 13.506), Liver Cancer (impact factor 11.740), Hypertension (impact factor 10.190), Canadian Medical Association Journal (impact factor 8.262), Alimentary Pharmacology & Therapeutics (impact factor 8.171), International Journal of Cancer (impact factor 7.396), Cancer (impact factor 6.860), Hepatology International (impact factor 6.047), Journal of Antimicrobial Chemotherapy (impact factor 5.790), Word Journal of Gastroenterology (impact factor 5.742), Clinical and Translational Gastroenterology (impact factor 4.488) and Cancer Epidemiology Biomarkers & Prevention (impact factor 4.254). He was invited to deliver 47 presentations (including oral plenary session) and lectures at international and local conferences and institutions. He currently serves as an Editorial Board member in Artificial Intelligence in Gastroenterology. He has been invited to be the reviewer of 17 international journals including Gut, Clinical Gastroenterology & Hepatology, Alimentary Pharmacology & Therapeutics, British Journal of Cancer, Journal of Gastroenterology & Hepatology, Hepatology International, Gut Pathogens, Digestive Diseases & Sciences, Cancer Medicine and PLOS ONE. 

Dr. Cheung was awarded the Professor Anthony Hedley Prize in Public Health for the highest place (with distinction in both written exam and thesis) in 2016 and the Sir Patrick Manson Gold Medal for his Doctor of Medicine thesis in 2020. He received the National Scholar Award at UEG Week 2021, APDWF/JGHG Young Investigator’s Award at Asian Pacific Digestive Week in 2017, Distinguished Research Paper Award for Young Investigator (2018 with Gold Medal Award, 2019, 2020 and 2021) from the Hong Kong College of Physicians, Faculty Outstanding Research Output Award (2018, 2019, 2020 and 2021) from the University of Hong Kong, Faculty Knowledge Exchange Award from the University of Hong Kong (2018), Best Abstract Award in Clinical Medicine in Medical Research Conference from the University of Hong Kong (2018, 2019, 2020 and 2021) as well as multiple other awards for abstract presentation in local and overseas conferences.

Dr. Cheung received the Health and Medical Research Fund (HMRF) from the Research Grant Council, the Government of HKSAR to conduct a research investigating the epidemiology, risk factors and chemopreventive agents of post-colonoscopy colorectal cancer in Hong Kong. He also received another HMRF to conduct a research investigating the epidemiology and risk factors of major osteoporotic fracture after Helicobacter pylori eradication and its interaction with proton pump inhibitors on fracture risk. In addition, he received an HMRF to conduct a commissioned research to investigate the role of gut microbiota in COVID-19 vaccine immunogenicity and adverse events.

Dr. Cheung was also the awardee of the Clinical Research Fellowship Programme and received the General Research Fund (GRF) from the Research Grant Council, the Government of HKSAR to conduct a 2-year project (2021-2022) which is a randomized controlled trial on treating fatty liver disease. In addition, he received another GRF to conduct a 3-year project (2022-2024) for a randomized controlled trial on preventing fibrosis and cirrhosis progression in chronic hepatitis B patients.


Research Profile

  1. Big data analysis
  2. Epidemiology and chemoprevention of gastrointestinal and hepatobiliary cancers
  3. Liver diseases including hepatitis B virus infection, fatty liver and liver cancer
  4. Gut microbiota
  5. Helicobacter pylori infection
  6. Gastrointestinal bleeding
  7. Inflammatory bowel disease
  8. COVID-19 disease

Selected Publications
  1. Cheung KS, Chan EW, Wong AYS, et al. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: A population-based study. Gut 2018;67:28-35 (impact factor 23.059)
  2. Cheung KS, Chen L, Chan EW, et al. Statins reduce the progression of non-advanced adenomas to colorectal cancer: a postcolonoscopy study in 187897 patients. Gut 2019;68:1979-1985 (impact factor 23.059)
  3. Cheung KS, Hung IF, Chan PP, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and meta-analysis. Gastroenterology 2020;159:81-95 (impact factor 22.682)
  4. Cheung KS, Hung IF, Leung WK. Association between famotidine use and COVID-19 severity in Hong Kong. Gastroenterology 2021;160:1898-1899 (impact factor 22.682)
  5. Leung WK, Wong IOL, Cheung KS, et al. Effects of Helicobacter pylori Treatment on Incidence of Gastric Cancer in Older Individuals. Gastroenterology 2018;155:67-75 (impact factor 22.682)
  6. Cheung KS, Chan EW, Chen L, et al. Diabetes mellitus increases risk of gastric cancer after Helicobacter pylori eradication: a territory-wide study with propensity score analysis. Diabetes Care 2019;42:1769-1775 (impact factor 19.112)
  7. Cheung KS, Chan EW, Wong AYS, et al. Metformin use and gastric cancer risk in diabetic patients after Helicobacter pylori eradication. J Natl Cancer Inst 2019;111: 484-489 (impact factor 13.506)
  8. Cheung KS, Chan EW, Wong AYS, et al. Aspirin and Risk of Gastric Cancer After Helicobacter pylori Eradication: A Territory-Wide Study. J Natl Cancer Inst 2018;110:743-749 (impact factor 13.506)
  9. Cheung KS, Lam LK, Seto WK, Leung WK. Use of antibiotics during immune checkpoint inhibitors associates with lower survival in hepatocellcular carcinoma. Liver Cancer 2021 [in press] (impact factor 11.740)
  10. Cheung KS, Chan EW, Wong AYS, et al. ACE (Angiotensin converting enzyme) inhibitors/angiotensin receptor blockers are associated with lower colorectal cancer risk: a territory-wide study with propensity score analysis. Hypertension 2020;76:968-975 (impact factor 10.190)
  11. Cheung KS, Hung IF, Leung WK. Association between angiotensin blockade and COVID-19 severity in Hong Kong. CMAJ 2020;192:E635 (impact factor 8.262)
  12. Cheung KS, Chen L, Chan EW, et al. Non-steroidal anti-inflammatory drugs but not aspirin are associated with a lower risk of post-colonoscopy colorectal cancer. Aliment Pharmacol Ther 2020;51:899-908 (impact factor 8.171)
  13. Li B*, Cheung KS*, Wong IYH, Leung WK, Law S. Calcium channel blockers are associated with lower gastric cancer risk: a territory-wide study with propensity score analysis. Int J Cancer 2021;148:2148-2157 (impact factor 7.396) * co-first authorship
  14. Li B*, Cheung KS*, Wong IYH, Leung WK, Law S. Non-aspirin non-steroidal anti-inflammatory drugs and gastric cancer risk after Helicobacter pylori eradication: a territory-wide study. Cancer 2021;127:1805-1815 (impact factor 6.860) * co-first authorship
  15. Cheung KS, Mak LY, Lam LK, Fung J, Liu F, Seto WK, Yuen MF. Statins associate with better clinical outcomes in chronic hepatitis B patients with HBsAg seroclearance. Hepatol Int 2021 [in press] (impact factor 6.047)
  16. Cheung KS, Seto WK, Lai CL, Yuen MF. Prevention and management of hepatitis B virus reactivation in cancer patients. Hepatol Int 2016;10:407-14 (impact factor 6.047)
  17. Lyu Tao,* Cheung KS,* Ni L, et al. High prevalence and risk factors of multiple antibiotic resistance in patients who fail first-line Helicobacter pylori therapy in southern China: a municipality-wide multi-center, prospective cohort study. J Antimicrob Chemother 2020;75:3391-3394 (impact factor 5.790) * co-first authorship
  18. Cheung KS, Seto WK, Leung WK. Application of Big Data analysis in gastrointestinal research. World J Gastroenterol 2019;25:2990-3008 (impact factor 5.742)
  19. Cheung KS, Seto WK, Fung J, et al. Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis. World J Gastroenterol 2017;23:7863-7874 (impact factor 5.742)
  20. Cheung KS, Seto WK, Fung J, et al. Epidemiology and natural history of Wilson's disease in the Chinese: A territory-based study in Hong Kong between 2000 and 2016. World J Gastroenterol 2017;23:7716-7726 (impact factor 5.742)
  21. Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World J Gastroenterol 2017;23:1954-1963 (impact factor 5.742)
  22. Cheung KS, Chung KL, Leung WK. Chemopreventive effect of metformin on gastric cancer development. Gut Liver 2021 [in press] (impact factor 4.519)
  23. Cheung KS*, Mak LY, Liu SH, Cheng HM, Seto WK, Yuen MF, Lai CL*. Entecavir vs tenofovir in hepatocellular carcinoma presentation in chronic hepatitis B infection: a systematic review and meta-analysis. Clin Transl Gastroenterol 2020;11:e00236 (impact factor 4.488) * co-corresponding authorship
  24. Cheung KS, Seto WK, Fung J, et al. Epidemiology and Natural History of Primary Biliary Cholangitis in the Chinese: A Territory-Based Study in Hong Kong between 2000 and 2015. Clin Transl Gastroenterol 2017;8:e116 (impact factor 4.488)
  25. Cheung KS, Seto WK, Fung J, et al. Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid. Clin Transl Gastroenterol 2017;8:e100 (impact factor 4.488)
  26. Cheung KS, Chan EW, Wong AYS, et al. Statins were associated with a reduced gastric cancer risk in patients with eradicated Helicobacter pylori infection: a territory-wide propensity score matched study. Cancer Epidemiol Biomarkers Prev 2020;29:493-499 (impact factor 4.254)
  27. Cheung KS, Seto WK, Wong DK, et al. Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy. J Viral Hepat 2017;24:654-661 (impact factor 3.728)
  28. Cheung KS, Chen L, Seto WK, Leung WK. Epidemiology, characteristics and survival of post-colonoscopy colorectal cancer in Asia: a population-based study. J Gastroenterol Hepatol 2019;34:1545-1553 (impact factor 3.522)

Awards and Prizes
  1. National Scholar Award UEG Week Virtual (2021)
  2. Faculty Outstanding Research Output Award, The University of Hong Kong (2021)
  3. Distinguished Research Paper Award for Young Investigator, Hong Kong College of Physicians (2021)
  4. Best Abstract Award in Clinical Medicine in 26th Medical Research Conference (eposter presentation), The University of Hong Kong (2021)
  5. Clinical Research Fellowship programme, Research Grant Council, The Government of HKSAR (2020/2021)
  6. Distinguished Research Paper Award for Young Investigator, Hong Kong College of Physicians (2020)
  7. Faculty Outstanding Research Output Award, The University of Hong Kong (2020)
  8. Best Abstract Award in Clinical Medicine in 25th Medical Research Conference (oral presentation), The University of Hong Kong (2020)
  9. Faculty Outstanding Research Output Award, The University of Hong Kong (2019)
  10. Travel Grant Award for oral abstract presentation, United European Gastroenterology Week (2019)
  11. Distinguished Research Paper Award for Young Investigator, Hong Kong College of Physicians (2019)
  12. Best Abstract Award in Clinical Medicine in 24th Medical Research Conference (oral presentation), The University of Hong Kong (2019)
  13. Faculty Outstanding Research Output Award, The University of Hong Kong (2018)
  14. Faculty Knowledge Exchange Award, The University of Hong Kong (2018)
  15. Sir Robert Black Trust Fund Postgraduate Scholarship (2018-2019)
  16. Distinguished Research Paper Award for Young Investigator (with Gold Medal Award), Hong Kong College of Physicians (2018)
  17. Best Poster Award, Silver Prize in 9th Asian-Pacific Topic Conference (2018)
  18. Best Abstract Award in Clinical Medicine in 23rd Medical Research Conference (oral presentation), The University of Hong Kong (2018)
  19. APDWF / JGHF Young Investigator’s Award, Asian Pacific Digestive Week (2017)
  20. Professor Anthony Hedley Prize in Public Health for highest place in Master of Public Health, The University of Hong Kong (2016)
  21. Distinction for both written exam and thesis in Master of Public Health, The University of Hong Kong (2016)
  22. Best Thesis Award for Exit Assessment Dissertations, Hong Kong College of Physicians (2015)

Grant Record

Research grants as principal investigator

  1. Health and Medical Research Fund, Commissioned Research on the Novel Coronavirus Disease (COVID-19), Food and Health Bureau, The Government of HKSAR, 2021 (Commissioned Research on the Novel Coronavirus Disease (COVID-19) (Ref no: COVID1903010; HKD $1,990,000)
  2. General Research Fund, Research Grant Council, The Government of HKSAR, 2021/2022 (Ref no: 17109321; HKD $1,125,732)
  3. Health and Medical Research Fund, Food and Health Bureau, The Government of HKSAR, 2019 (Ref no: 18191921; HKD $958,936)
  4. General Research Fund & Clinical Research Fellowship Programme, Research Grant Council, The Government of HKSAR, 2020/2021 (Ref no: 17110420; HKD $2,093,053)
  5. Start-up Fund, The University of Hong Kong, 2019 (HKD $1,850,000)
  6. Health and Medical Research Fund, Food and Health Bureau, The Government of HKSAR, 2017 (Ref no: 16173001; HKD $619,520)
  7. URC Seed Funding for Basic Research for New Staff (Ref no: 201904185020; HKD $150,000)
  8. Young Investigator Research Grant, Hong Kong College of Physicians, 2021 (HKD $50,000)
  9. Young Investigator Research Grant, Hong Kong College of Physicians, 2020 (HKD $50,000)
  10. Young Investigator Research Grant, Hong Kong College of Physicians, 2018 (HKD $50,000)
  11. Young Investigator Research Grant, Hong Kong College of Physicians, 2016 (HKD $50,000)